PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma

被引：0
|
作者：
Sang Kyum Kim
Jee Hung Kim
Seung Hyun Kim
Young Han Lee
Jung Woo Han
Wooyeol Baek
Ha Young Woo
Min Kyung Jeon
Hyo Song Kim
机构：
[1] Yonsei University College of Medicine,Department of Pathology
[2] Gangnam Severance Hospital,Division of Medical Oncology, Department of Internal Medicine
[3] Yonsei University College of Medicine,Department of Orthopedic Surgery
[4] Yonsei University College of Medicine,Department of Radiology
[5] Yonsei University College of Medicine,Division of Pediatric Hemato
[6] Yonsei University College of Medicine,Oncology, Department of Pediatrics
[7] Yonsei University College of Medicine,Department of Plastic Surgery
[8] Yonsei Cancer Center,Division of Medical Oncology, Department of Internal Medicine
[9] Yonsei University College of Medicine,undefined
来源：
BMC Cancer | / 21卷
关键词：
Soft tissue sarcoma; Pazopanib; PD-L1; Biomarker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1
    Darabi, Sourat
    Braxton, David R.
    Eisenberg, Burton L.
    Demeure, Michael J.
    ONCOLOGY-NEW YORK, 2020, 34 (08): : 321 - 327
  • [32] PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer
    Raimondi, Lucrezia
    Raimondi, Filippo Maria
    Di Benedetto, Laura
    Cimino, Giuseppe
    Spinelli, Gian Paolo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (18) : 1 - 13
  • [33] Modeling tumour heterogeneity of PD-L1 expression in tumour progression and adaptive therapy
    Shizhao Ma
    Jinzhi Lei
    Xiulan Lai
    Journal of Mathematical Biology, 2023, 86
  • [34] THE INVESTIGATION OF PD-L1 EXPRESSION AS A PROGNOSTIC MARKER FOR UTERINE SARCOMA
    Sukhin, V. S.
    Danyliuk, S. V.
    Sukhina, O. N.
    Zadnepryanniy, A. Z.
    Lindquist, D.
    Hermelin, H.
    Tarjan, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 568 - 568
  • [35] Modeling tumour heterogeneity of PD-L1 expression in tumour progression and adaptive therapy
    Ma, Shizhao
    Lei, Jinzhi
    Lai, Xiulan
    JOURNAL OF MATHEMATICAL BIOLOGY, 2023, 86 (03)
  • [36] Immune regulation of canine tumour and macrophage PD-L1 expression
    Hartley, G.
    Faulhaber, E.
    Caldwell, A.
    Coy, J.
    Kurihara, J.
    Guth, A.
    Regan, D.
    Dow, S.
    VETERINARY AND COMPARATIVE ONCOLOGY, 2017, 15 (02) : 534 - 549
  • [37] PD-L1 and IDO-1 expression in undifferentiated pleomorphic sarcoma
    Ishihara, Shin
    Yamada, Yuichi
    Toda, Yu
    Kohashi, Kenichi
    Yamamoto, Hidetaka
    Oda, Yoshinao
    CANCER SCIENCE, 2021, 112 : 411 - 411
  • [38] COST EFFECTIVENESS OF PAZOPANIB IN SOFT TISSUE SARCOMA
    Amdahl, J.
    Manson, S.
    Isbell, R.
    Chit, A. N.
    Diaz, J. R.
    Lewis, L.
    Delea, T. E.
    VALUE IN HEALTH, 2012, 15 (07) : A423 - A424
  • [39] Pazopanib for metastatic soft-tissue sarcoma
    Endo, Makoto
    Nielsen, Torsten O.
    LANCET, 2012, 380 (9844): : 801 - 801
  • [40] Pazopanib for the treatment of soft-tissue sarcoma
    Heudel, Pierre
    Cassier, Philippe
    Derbel, Olfa
    Dufresne, Armelle
    Meeus, Pierre
    Thiesse, Philippe
    Ranchere-Vince, Dominique
    Blay, Jean Yves
    Ray-Coquard, Isabelle
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2012, 4 : 65 - 70
12345